Download PDF
Semin Neurol 2019; 39(05): 578-588
DOI: 10.1055/s-0039-1688994
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Neuropathy Associated with Systemic Amyloidosis

Michelle Kaku
1   Department of Neurology, Boston Medical Center, Boston, Massachusetts
2   Amyloidosis Center, Boston Medical Center, Boston University, Boston, Massachusetts
,
John L. Berk
2   Amyloidosis Center, Boston Medical Center, Boston University, Boston, Massachusetts
3   Department of Pulmonology, Boston Medical Center, Boston, Massachusetts
› Author Affiliations
Further Information

Publication History

Publication Date:
22 October 2019 (online)

   Permissions and Reprints

Abstract

Peripheral neuropathy occurs in the setting of both hereditary and acquired amyloidosis. The most common form of hereditary amyloidosis is caused by 1 of 140 mutations in the transthyretin (TTR) gene, which can lead to neuropathic hereditary transthyretin amyloidosis (hATTR; previously referred to as transthyretin familial amyloid polyneuropathy), whereas acquired immunoglobulin light chain (AL) amyloidosis is the most common acquired form. Patients typically present with a sensorimotor polyneuropathy, focal neuropathy such as carpal tunnel syndrome, or autonomic neuropathy. When neuropathy is the sole or dominant presenting symptom, the diagnosis is commonly delayed. With the advent of new drug therapies for AL amyloidosis and hATTR amyloidosis, including proteasome inhibitors, TTR silencers, and TTR protein stabilizers, the neurologist is uniquely positioned to diagnose neurologic manifestations of systemic amyloidosis, leading to earlier disease identification and treatment. This article reviews the epidemiology, clinical presentations, pathophysiology, diagnostic workup, and treatment of neuropathy in the setting of amyloidosis.

Keywords

hereditary neuropathy - transthyretin - AL amyloidosis - primary amyloidosis
 

  • References

  • 1 Planté-Bordeneuve V, Lalu T, Misrahi M. , et al. Genotypic-phenotypic variations in a series of 65 patients with familial amyloid polyneuropathy. Neurology 1998; 51 (03) 708-714
    CrossrefPubMedGoogle Scholar
  • 2 Robbins J. Thyroxine-binding proteins. Prog Clin Biol Res 1976; 5: 331-355
    PubMedGoogle Scholar
  • 3 Wallace MR, Naylor SL, Kluve-Beckerman B. , et al. Localization of the human prealbumin gene to chromosome 18. Biochem Biophys Res Commun 1985; 129 (03) 753-758
    CrossrefPubMedGoogle Scholar
  • 4 Dickson PW, Aldred AR, Marley PD, Tu GF, Howlett GJ, Schreiber G. High prealbumin and transferrin mRNA levels in the choroid plexus of rat brain. Biochem Biophys Res Commun 1985; 127 (03) 890-895
    CrossrefPubMedGoogle Scholar
  • 5 Soprano DR, Herbert J, Soprano KJ, Schon EA, Goodman DS. Demonstration of transthyretin mRNA in the brain and other extrahepatic tissues in the rat. J Biol Chem 1985; 260 (21) 11793-11798
    CrossrefPubMedGoogle Scholar
  • 6 Andrade C. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 1952; 75 (03) 408-427
    CrossrefPubMedGoogle Scholar
  • 7 Andersson R. Familial amyloidosis with polyneuropathy: a clinical study based on patients living in northern Sweden. Acta Med Scand Suppl 1976; 590: 1-64
    PubMedGoogle Scholar
  • 8 Araki S, Mawatari S, Ohta M, Nakajima A, Kuroiwa Y. Polyneuritic amyloidosis in a Japanese family. Arch Neurol 1968; 18 (06) 593-602
    CrossrefPubMedGoogle Scholar
  • 9 Schmidt HH, Waddington-Cruz M, Botteman MF. , et al. Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. Muscle Nerve 2018; 57 (05) 829-837
    CrossrefPubMedGoogle Scholar
  • 10 Plante-Bordeneuve V. Update in the diagnosis and management of transthyretin familial amyloid polyneuropathy. J Neurol 2014; 261 (06) 1227-1233
    CrossrefPubMedGoogle Scholar
  • 11 Maurer MS, Hanna M, Grogan M. , et al; THAOS Investigators. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol 2016; 68 (02) 161-172
    CrossrefPubMedGoogle Scholar
  • 12 Yamashita T, Hamidi Asl K, Yazaki M, Benson MD. A prospective evaluation of the transthyretin Ile122 allele frequency in an African-American population. Amyloid 2005; 12 (02) 127-130
    CrossrefPubMedGoogle Scholar
  • 13 Connors LH, Prokaeva T, Lim A. , et al. Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J 2009; 158 (04) 607-614
    CrossrefPubMedGoogle Scholar
  • 14 Hellman U, Alarcon F, Lundgren HE, Suhr OB, Bonaïti-Pellié C, Planté-Bordeneuve V. Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid 2008; 15 (03) 181-186
    CrossrefPubMedGoogle Scholar
  • 15 Plante-Bordeneuve V, Carayol J, Ferreira A. , et al. Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families. J Med Genet 2003; 40: e120-e120
    CrossrefPubMedGoogle Scholar
  • 16 Lemos C, Coelho T, Alves-Ferreira M. , et al. Overcoming artefact: anticipation in 284 Portuguese kindreds with familial amyloid polyneuropathy (FAP) ATTRV30M. J Neurol Neurosurg Psychiatry 2014; 85 (03) 326-330
    CrossrefPubMedGoogle Scholar
  • 17 Takahashi K, Yi S, Kimura Y, Araki S. Familial amyloidotic polyneuropathy type 1 in Kumamoto, Japan: a clinicopathologic, histochemical, immunohistochemical, and ultrastructural study. Hum Pathol 1991; 22 (06) 519-527
    CrossrefPubMedGoogle Scholar
  • 18 Ikeda S, Yanagisawa N, Hongo M, Ito N. Vagus nerve and celiac ganglion lesions in generalized amyloidosis. A correlative study of familial amyloid polyneuropathy and AL-amyloidosis. J Neurol Sci 1987; 79 (1-2): 129-139
    CrossrefPubMedGoogle Scholar
  • 19 Kelly Jr JJ, Kyle RA, O'Brien PC, Dyck PJ. The natural history of peripheral neuropathy in primary systemic amyloidosis. Ann Neurol 1979; 6 (01) 1-7
    CrossrefPubMedGoogle Scholar
  • 20 Dyck PJ, Lambert EH. Dissociated sensation in amyloidosis. Compound action potential, quantitative histologic and teased-fiber, and electron microscopic studies of sural nerve biopsies. Arch Neurol 1969; 20 (05) 490-507
    CrossrefPubMedGoogle Scholar
  • 21 Planté-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol 2011; 10 (12) 1086-1097
    CrossrefPubMedGoogle Scholar
  • 22 Koike H, Ikeda S, Takahashi M. , et al. Schwann cell and endothelial cell damage in transthyretin familial amyloid polyneuropathy. Neurology 2016; 87 (21) 2220-2229
    CrossrefPubMedGoogle Scholar
  • 23 Verghese JP, Bradley WG, Nemni R, McAdam KP. Amyloid neuropathy in multiple myeloma and other plasma cell dyscrasias. A hypothesis of the pathogenesis of amyloid neuropathies. J Neurol Sci 1983; 59 (02) 237-246
    CrossrefPubMedGoogle Scholar
  • 24 Adams D, Suhr OB, Hund E. , et al. First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol 2016; 29: S14
    CrossrefPubMedGoogle Scholar
  • 25 Thomas PK, King RH. Peripheral nerve changes in amyloid neuropathy. Brain 1974; 97 (02) 395-406
    CrossrefPubMedGoogle Scholar
  • 26 Rowe K, Pankow J, Nehme F, Salyers W. Gastrointestinal amyloidosis: review of the literature. Cureus 2017; 9 (05) e1228
    PubMedGoogle Scholar
  • 27 Rubinow A, Cohen AS. Scalloped pupils in familial amyloid polyneuropathy. Arthritis Rheum 1986; 29 (03) 445-447
    CrossrefPubMedGoogle Scholar
  • 28 Adams D, Samuel D, Goulon-Goeau C. , et al. The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. Brain 2000; 123 (Pt 7): 1495-1504
    CrossrefPubMedGoogle Scholar
  • 29 Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 2007; 36 (04) 411-423
    CrossrefPubMedGoogle Scholar
  • 30 Sousa A, Andersson R, Drugge U, Holmgren G, Sandgren O. Familial amyloidotic polyneuropathy in Sweden: geographical distribution, age of onset, and prevalence. Hum Hered 1993; 43 (05) 288-294
    CrossrefPubMedGoogle Scholar
  • 31 Ikeda S, Nakazato M, Ando Y, Sobue G. Familial transthyretin-type amyloid polyneuropathy in Japan: clinical and genetic heterogeneity. Neurology 2002; 58 (07) 1001-1007
    CrossrefPubMedGoogle Scholar
  • 32 Yamashita T, Ueda M, Misumi Y. , et al. Genetic and clinical characteristics of hereditary transthyretin amyloidosis in endemic and non-endemic areas: experience from a single-referral center in Japan. J Neurol 2018; 265 (01) 134-140
    CrossrefPubMedGoogle Scholar
  • 33 Sekijima Y, Ueda M, Koike H, Misawa S, Ishii T, Ando Y. Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm. Orphanet J Rare Dis 2018; 13: 6
    CrossrefPubMedGoogle Scholar
  • 34 Théaudin M, Lozeron P, Algalarrondo V. , et al. Upper limb onset of hereditary transthyretin amyloidosis is common in non-endemic areas. Eur J Neurol 2019; 26 (03) 497-e36
    CrossrefPubMedGoogle Scholar
  • 35 Togashi S, Watanabe H, Nagasaka T. , et al. An aggressive familial amyloidotic polyneuropathy caused by a new variant transthyretin Lys 54. Neurology 1999; 53 (03) 637-639
    CrossrefPubMedGoogle Scholar
  • 36 Adams D, Lozeron P, Theaudin M. , et al; French Network for FAP. Regional difference and similarity of familial amyloidosis with polyneuropathy in France. Amyloid 2012; 19 (Suppl. 01) 61-64
    PubMedGoogle Scholar
  • 37 Dohrn MF, Röcken C, De Bleecker JL. , et al. Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy. J Neurol 2013; 260 (12) 3093-3108
    CrossrefPubMedGoogle Scholar
  • 38 Ando Y, Suhr OB. Autonomic dysfunction in familial amyloidotic polyneuropathy (FAP). Amyloid 1998; 5 (04) 288-300
    CrossrefPubMedGoogle Scholar
  • 39 Saeki Y, Ueno S, Yorifuji S, Sugiyama Y, Ide Y, Matsuzawa Y. New mutant gene (transthyretin Arg 58) in cases with hereditary polyneuropathy detected by non-isotope method of single-strand conformation polymorphism analysis. Biochem Biophys Res Commun 1991; 180 (01) 380-385
    CrossrefPubMedGoogle Scholar
  • 40 Murakami T, Tachibana S, Endo Y. , et al. Familial carpal tunnel syndrome due to amyloidogenic transthyretin His 114 variant. Neurology 1994; 44 (02) 315-318
    CrossrefPubMedGoogle Scholar
  • 41 Zólyomi Z, Benson MD, Halász K, Uemichi T, Fekete G. Transthyretin mutation (serine 84) associated with familial amyloid polyneuropathy in a Hungarian family. Amyloid 1998; 5 (01) 30-34
    CrossrefPubMedGoogle Scholar
  • 42 Mazzeo A, Russo M, Di Bella G. , et al. TTR-FAP: a single-center experience in Sicily, an Italian endemic area. J Neuromuscul Dis 2015; 42 (09) S31-S32
    PubMedGoogle Scholar
  • 43 Ikram A, Sperry B, Reyes B, Seitz W, Hanna M. Carpal tunnel syndrome and amyloid cardiomyopathy. J Cardiac Failure 2017; 23: S11-S12
    PubMedGoogle Scholar
  • 44 Yanagisawa A, Ueda M, Sueyoshi T. , et al. Amyloid deposits derived from transthyretin in the ligamentum flavum as related to lumbar spinal canal stenosis. Mod Pathol 2015; 28 (02) 201-207
    Google Scholar
  • 45 Liewluck T, Milone M. Characterization of isolated amyloid myopathy. Eur J Neurol 2017; 24 (12) 1437-1445
    CrossrefPubMedGoogle Scholar
  • 46 Yamashita T, Ando Y, Katsuragi S. , et al. Muscular amyloid angiopathy with amyloidgenic transthyretin Ser50Ile and Tyr114Cys. Muscle Nerve 2005; 31 (01) 41-45
    CrossrefPubMedGoogle Scholar
  • 47 Carr AS, Pelayo-Negro AL, Jaunmuktane Z. , et al. Transthyretin V122I amyloidosis with clinical and histological evidence of amyloid neuropathy and myopathy. Neuromuscul Disord 2015; 25 (06) 511-515
    CrossrefPubMedGoogle Scholar
  • 48 Ellie E, Camou F, Vital A. , et al. Recurrent subarachnoid hemorrhage associated with a new transthyretin variant (Gly53Glu). Neurology 2001; 57 (01) 135-137
    CrossrefPubMedGoogle Scholar
  • 49 Uemichi T, Uitti RJ, Koeppen AH, Donat JR, Benson MD. Oculoleptomeningeal amyloidosis associated with a new transthyretin variant Ser64. Arch Neurol 1999; 56 (09) 1152-1155
    CrossrefPubMedGoogle Scholar
  • 50 Mathieu F, Morgan E, So J, Munoz DG, Mason W, Kongkham P. Oculoleptomeningeal amyloidosis secondary to the rare transthyretin c.381T>G (p.Ile127Met) mutation. World Neurosurg 2018; 111: 190-193
    CrossrefPubMedGoogle Scholar
  • 51 Benson MD. Leptomeningeal amyloid and variant transthyretins. Am J Pathol 1996; 148 (02) 351-354
    PubMedGoogle Scholar
  • 52 Petersen RB, Goren H, Cohen M. , et al. Transthyretin amyloidosis: a new mutation associated with dementia. Ann Neurol 1997; 41 (03) 307-313
    CrossrefPubMedGoogle Scholar
  • 53 Brett M, Persey MR, Reilly MM. , et al. Transthyretin Leu12Pro is associated with systemic, neuropathic and leptomeningeal amyloidosis. Brain 1999; 122 (Pt 2): 183-190
    CrossrefPubMedGoogle Scholar
  • 54 Blevins G, Macaulay R, Harder S. , et al. Oculoleptomeningeal amyloidosis in a large kindred with a new transthyretin variant Tyr69His. Neurology 2003; 60 (10) 1625-1630
    CrossrefPubMedGoogle Scholar
  • 55 Herrick MK, DeBruyne K, Horoupian DS, Skare J, Vanefsky MA, Ong T. Massive leptomeningeal amyloidosis associated with a Val30Met transthyretin gene. Neurology 1996; 47 (04) 988-992
    CrossrefPubMedGoogle Scholar
  • 56 Martins da Silva A, Cavaco S, Fernandes J. , et al. Age-dependent cognitive dysfunction in untreated hereditary transthyretin amyloidosis. J Neurol 2018; 265 (02) 299-307
    CrossrefPubMedGoogle Scholar
  • 57 Planté-Bordeneuve V, Ferreira A, Lalu T. , et al. Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology 2007; 69 (07) 693-698
    CrossrefPubMedGoogle Scholar
  • 58 Coelho T, Vinik A, Vinik EJ. , et al. Clinical measures in transthyretin familial amyloid polyneuropathy. Muscle Nerve 2017; 55: 323-332
    CrossrefPubMedGoogle Scholar
  • 59 Kyle RA, Greipp PR. Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clin Proc 1983; 58 (10) 665-683
    PubMedGoogle Scholar
  • 60 Vucic S, Chong PST, Cros D. Atypical presentations of primary amyloid neuropathy. Muscle Nerve 2003; 28 (06) 696-702
    CrossrefPubMedGoogle Scholar
  • 61 Tracy JA, Dyck PJ, Dyck PJ. Primary amyloidosis presenting as upper limb multiple mononeuropathies. Muscle Nerve 2010; 41 (05) 710-715
    CrossrefPubMedGoogle Scholar
  • 62 Rajkumar SV, Gertz MA, Kyle RA. Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy. Am J Med 1998; 104 (03) 232-237
    CrossrefPubMedGoogle Scholar
  • 63 Escolano-Lozano F, Barreiros AP, Birklein F, Geber C. Transthyretin familial amyloid polyneuropathy (TTR-FAP): Parameters for early diagnosis. Brain Behav 2017; 8 (01) e00889
    PubMedGoogle Scholar
  • 64 Seixas A, Vilas-Boas MdC, Carvalho R. , et al. Skin temperature of the foot: comparing transthyretin familial amyloid polyneuropathy and diabetic foot patients. Comput Methods Biomech Biomed Eng Imaging Vis 2018; 1-8
    PubMedGoogle Scholar
  • 65 Lozeron P, Mariani L-L, Dodet P. , et al. Transthyretin amyloid polyneuropathies mimicking a demyelinating polyneuropathy. Neurology 2018; 91 (02) e143-e152
    CrossrefPubMedGoogle Scholar
  • 66 Yang N-C, Lee M-J, Chao C-C. , et al. Clinical presentations and skin denervation in amyloid neuropathy due to transthyretin Ala97Ser. Neurology 2010; 75 (06) 532-538
    CrossrefPubMedGoogle Scholar
  • 67 Masuda T, Ueda M, Suenaga G. , et al. Early skin denervation in hereditary and iatrogenic transthyretin amyloid neuropathy. Neurology 2017; 88 (23) 2192-2197
    CrossrefPubMedGoogle Scholar
  • 68 Lefaucheur J-P, Ng Wing Tin S, Kerschen P, Damy T, Planté-Bordeneuve V. Neurophysiological markers of small fibre neuropathy in TTR-FAP mutation carriers. J Neurol 2013; 260 (06) 1497-1503
    CrossrefPubMedGoogle Scholar
  • 69 Ebenezer GJ, Liu Y, Judge DP. , et al. Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy. Ann Neurol 2017; 82 (01) 44-56
    CrossrefPubMedGoogle Scholar
  • 70 Simmons Z, Blaivas M, Aguilera AJ, Feldman EL, Bromberg MB, Towfighi J. Low diagnostic yield of sural nerve biopsy in patients with peripheral neuropathy and primary amyloidosis. J Neurol Sci 1993; 120 (01) 60-63
    CrossrefPubMedGoogle Scholar
  • 71 Buxbaum JN, Tagoe CE. The genetics of the amyloidoses. Annu Rev Med 2000; 51: 543-569
    CrossrefPubMedGoogle Scholar
  • 72 Cappellari M, Cavallaro T, Ferrarini M. , et al. Variable presentations of TTR-related familial amyloid polyneuropathy in seventeen patients. J Peripher Nerv Syst 2011; 16 (02) 119-129
    CrossrefPubMedGoogle Scholar
  • 73 Luigetti M, Conte A, Del Grande A. , et al. TTR-related amyloid neuropathy: Clinical, electrophysiological and pathological findings in fifteen unrelated patients. Neurol Sci 2013; 34: 1057-1063
    CrossrefPubMedGoogle Scholar
  • 74 Samões R, Taipa R, Valdrez K. , et al. Amyloid detection in the transverse carpal ligament of patients with hereditary ATTR V30M amyloidosis and carpal tunnel syndrome. Amyloid 2017; 24 (02) 73-77
    CrossrefPubMedGoogle Scholar
  • 75 Kollmer J, Sahm F, Hegenbart U. , et al. Sural nerve injury in familial amyloid polyneuropathy: MR neurography vs clinicopathologic tools. Neurology 2017; 89 (05) 475-484
    CrossrefPubMedGoogle Scholar
  • 76 Freeman R, Abuzinadah AR, Gibbons C, Jones P, Miglis MG, Sinn DI. Orthostatic hypotension: JACC state-of-the-art review. J Am Coll Cardiol 2018; 72: 1294-1309
    CrossrefPubMedGoogle Scholar
  • 77 Wixner J, Suhr OB, Anan I. Management of gastrointestinal complications in hereditary transthyretin amyloidosis: a single-center experience over 40 years. Expert Rev Gastroenterol Hepatol 2018; 12: 73-81
    CrossrefPubMedGoogle Scholar
  • 78 Holmgren G, Steen L, Ekstedt J. , et al. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet 1991; 40 (03) 242-246
    PubMedGoogle Scholar
  • 79 Yamashita T, Ando Y, Okamoto S. , et al. Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy. Neurology 2012; 78 (09) 637-643
    CrossrefPubMedGoogle Scholar
  • 80 Suhr OB, Larsson M, Ericzon BG, Wilczek HE. ; FAPWTRʼs Investigators. Survival after transplantation in patients with mutations other than Val30Met: extracts from the FAP World Transplant Registry. Transplantation 2016; 100 (02) 373-381
    CrossrefPubMedGoogle Scholar
  • 81 Liepnieks JJ, Zhang LQ, Benson MD. Progression of transthyretin amyloid neuropathy after liver transplantation. Neurology 2010; 75 (04) 324-327
    CrossrefPubMedGoogle Scholar
  • 82 Sekijima Y, Yazaki M, Oguchi K. , et al. Cerebral amyloid angiopathy in posttransplant patients with hereditary ATTR amyloidosis. Neurology 2016; 87 (08) 773-781
    CrossrefPubMedGoogle Scholar
  • 83 Miller SR, Sekijima Y, Kelly JW. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest 2004; 84 (05) 545-552
    PubMedGoogle Scholar
  • 84 Berk JL, Suhr OB, Obici L. , et al; Diflunisal Trial Consortium. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 2013; 310 (24) 2658-2667
    CrossrefPubMedGoogle Scholar
  • 85 Sekijima Y, Tojo K, Morita H, Koyama J, Ikeda S. Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis. Amyloid 2015; 22 (02) 79-83
    CrossrefPubMedGoogle Scholar
  • 86 Whelan C, Sattianayagam P, Dungu J. , et al. Tolerability of diflunisal therapy in patients with transthyretin amyloidosis. XIIIth International Symposium on Amyloidosis May Groningen, Netherlands. Abstract OP 56; 2012
    PubMedGoogle Scholar
  • 87 Coelho T, Maia LF, Martins da Silva A. , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012; 79 (08) 785-792
    CrossrefPubMedGoogle Scholar
  • 88 Coelho T, Maia LF, da Silva AM. , et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol 2013; 260 (11) 2802-2814
    CrossrefPubMedGoogle Scholar
  • 89 Waddington Cruz M, Amass L, Keohane D, Schwartz J, Li H, Gundapaneni B. Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy. Amyloid 2016; 23 (03) 178-183
    CrossrefPubMedGoogle Scholar
  • 90 Coelho T, Inês M, Conceição I, Soares M, de Carvalho M, Costa J. Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy. Neurology 2018; 91: e1999-e2009
    CrossrefPubMedGoogle Scholar
  • 91 Benson MD, Waddington-Cruz M, Berk JL. , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 2018; 379 (01) 22-31
    CrossrefPubMedGoogle Scholar
  • 92 Berk J, Wang AK, Coelho T. , et al. Burden of hereditary transthyretin amyloidosis with polyneuropathy in patients enrolled in the Phase 3 study NEURO-TTR (P1. 331). AAN Enterprises, 2018. Available at: https://n.neurology.org/content/90/15_Supplement/P1.331 . Accessed April 24, 2019
    PubMedGoogle Scholar
  • 93 Adams D, Gonzalez-Duarte A, O'Riordan WD. , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379 (01) 11-21
    CrossrefPubMedGoogle Scholar
  • 94 Van Allen MW, Frohlich JA, Davis JR. Inherited predisposition to generalized amyloidosis. Clinical and pathological study of a family with neuropathy, nephropathy, and peptic ulcer. Neurology 1969; 19 (01) 10-25
    CrossrefPubMedGoogle Scholar
  • 95 Nichols WC, Gregg RE, Brewer Jr HB, Benson MD. A mutation in apolipoprotein A-I in the Iowa type of familial amyloidotic polyneuropathy. Genomics 1990; 8 (02) 318-323
    CrossrefPubMedGoogle Scholar
  • 96 Joy T, Wang J, Hahn A, Hegele RA. APOA1 related amyloidosis: a case report and literature review. Clin Biochem 2003; 36 (08) 641-645
    CrossrefPubMedGoogle Scholar
  • 97 de Sousa MM, Vital C, Ostler D. , et al. Apolipoprotein AI and transthyretin as components of amyloid fibrils in a kindred with apoAI Leu178His amyloidosis. Am J Pathol 2000; 156 (06) 1911-1917
    CrossrefPubMedGoogle Scholar
  • 98 Testro AG, Brennan SO, Macdonell RA, Hawkins PN, Angus PW. Hereditary amyloidosis with progressive peripheral neuropathy associated with apolipoprotein AI Gly26Arg: outcome of hepatorenal transplantation. Liver Transpl 2007; 13 (07) 1028-1031
    CrossrefPubMedGoogle Scholar
  • 99 Kiuru S, Seppäläinen AM. Neuropathy in familial amyloidosis, Finnish type (FAF): electrophysiological studies. Muscle Nerve 1994; 17 (03) 299-304
    CrossrefPubMedGoogle Scholar
  • 100 Meretoja J. Familial systemic paramyloidosis with lattice dystrophy of the cornea, progressive cranial neuropathy, skin changes and various internal symptoms. A previously unrecognized heritable syndrome. Ann Clin Res 1969; 1 (04) 314-324
    PubMedGoogle Scholar
  • 101 Kiuru S. Familial amyloidosis of the Finnish type (FAF). A clinical study of 30 patients. Acta Neurol Scand 1992; 86 (04) 346-353
    PubMedGoogle Scholar
  • 102 Boysen G, Galassi G, Kamieniecka Z, Schlaeger J, Trojaborg W. Familial amyloidosis with cranial neuropathy and corneal lattice dystrophy. J Neurol Neurosurg Psychiatry 1979; 42 (11) 1020-1030
    CrossrefPubMedGoogle Scholar
  • 103 Sunada Y, Shimizu T, Nakase H. , et al. Inherited amyloid polyneuropathy type IV (gelsolin variant) in a Japanese family. Ann Neurol 1993; 33 (01) 57-62
    CrossrefPubMedGoogle Scholar
  • 104 Kiuru S, Salonen O, Haltia M. Gelsolin-related spinal and cerebral amyloid angiopathy. Ann Neurol 1999; 45 (03) 305-311
    CrossrefPubMedGoogle Scholar
  • 105 Kiuru S, Matikainen E, Kupari M, Haltia M, Palo J. Autonomic nervous system and cardiac involvement in familial amyloidosis, Finnish type (FAF). J Neurol Sci 1994; 126 (01) 40-48
    CrossrefPubMedGoogle Scholar
  • 106 Kiuru-Enari S, Somer H, Seppäläinen A-M, Notkola I-L, Haltia M. Neuromuscular pathology in hereditary gelsolin amyloidosis. J Neuropathol Exp Neurol 2002; 61 (06) 565-571
    CrossrefPubMedGoogle Scholar
  • 107 Gertz MA, Lacy MQ, Dispenzieri A. Amyloidosis: recognition, confirmation, prognosis, and therapy. Mayo Clin Proc 1999; 74 (05) 490-494
    CrossrefPubMedGoogle Scholar
  • 108 Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995; 32 (01) 45-59
    PubMedGoogle Scholar
  • 109 Duston MA, Skinner M, Anderson J, Cohen AS. Peripheral neuropathy as an early marker of AL amyloidosis. Arch Intern Med 1989; 149 (02) 358-360
    CrossrefPubMedGoogle Scholar
  • 110 Matsuda M, Gono T, Morita H, Katoh N, Kodaira M, Ikeda S. Peripheral nerve involvement in primary systemic AL amyloidosis: a clinical and electrophysiological study. Eur J Neurol 2011; 18 (04) 604-610
    CrossrefPubMedGoogle Scholar
  • 111 Adams D, Lozeron P, Theaudin M. , et al. Varied patterns of inaugural light-chain (AL) amyloid polyneuropathy: a monocentric study of 24 patients. Amyloid 2011; 18 (Suppl. 01) 98-100
    PubMedGoogle Scholar
  • 112 Luigetti M, Papacci M, Bartoletti S, Marcaccio A, Romano A, Sabatelli M. AL amyloid neuropathy mimicking a chronic inflammatory demyelinating polyneuropathy. Amyloid 2012; 19 (01) 53-55
    PubMedGoogle Scholar
  • 113 Mathis S, Magy L, Diallo L, Boukhris S, Vallat JM. Amyloid neuropathy mimicking chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2012; 45 (01) 26-31
    CrossrefPubMedGoogle Scholar
  • 114 Cheng RR, Eskandari R, Welsh CT, Varma AK. A case of isolated amyloid light-chain amyloidosis of the radial nerve. J Neurosurg 2016; 125 (03) 598-602
    CrossrefPubMedGoogle Scholar
  • 115 Little KH, Lee EL, Frenkel EP. Cranial nerve deficits due to amyloidosis associated with plasma cell dyscrasia. South Med J 1986; 79 (06) 677-681
    CrossrefPubMedGoogle Scholar
  • 116 Traynor AE, Gertz MA, Kyle RA. Cranial neuropathy associated with primary amyloidosis. Ann Neurol 1991; 29 (04) 451-454
    CrossrefPubMedGoogle Scholar
  • 117 Massey EW, Massey JM. Facial diplegia due to amyloidosis. South Med J 1986; 79 (11) 1458-1459
    CrossrefPubMedGoogle Scholar
  • 118 Liewluck T, Milone M. Amyloid myopathy with and without systemic amyloidosis (S54.006). Neurology 2017; 88: S54
    PubMedGoogle Scholar
  • 119 Kahn SN, Bina M. Sensitivity of immunofixation electrophoresis for detecting IgM paraproteins in serum. Clin Chem 1988; 34 (08) 1633-1635
    CrossrefPubMedGoogle Scholar
  • 120 Abraham RS, Katzmann JA, Clark RJ, Bradwell AR, Kyle RA, Gertz MA. Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol 2003; 119 (02) 274-278
    CrossrefPubMedGoogle Scholar
  • 121 Katzmann JA, Clark RJ, Abraham RS. , et al. Serum reference intervals and diagnostic ranges for free κ and free λ immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002; 48 (09) 1437-1444
    CrossrefPubMedGoogle Scholar
  • 122 Wang A, Gorevic P. Neurologic Improvement after Cervical Decompression in Wild-Type Transthyretin Amyloidosis. Companion to Peripheral Neuropathy: Illustrated Cases and New Developments. Philadelphia, PA: Elsevier Saunders; 2010: 145-149
    Google Scholar
  • 123 Dingli D, Tan TS, Kumar SK. , et al. Stem cell transplantation in patients with autonomic neuropathy due to primary (AL) amyloidosis. Neurology 2010; 74 (11) 913-918
    CrossrefPubMedGoogle Scholar
  • 124 Gertz MA, Kyle RA, Greipp PR. Response rates and survival in primary systemic amyloidosis. Blood 1991; 77 (02) 257-262
    CrossrefPubMedGoogle Scholar
  • 125 Katoh N, Matsuda M, Yoshida T. , et al. Primary AL amyloid polyneuropathy successfully treated with high-dose melphalan followed by autologous stem cell transplantation. Muscle Nerve 2010; 41 (01) 138-143
    CrossrefPubMedGoogle Scholar
  • 126 Skinner M, Sanchorawala V, Seldin DC. , et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004; 140 (02) 85-93
    PubMedGoogle Scholar
  • 127 Kyle RA, Gertz MA, Greipp PR. , et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997; 336 (17) 1202-1207
    CrossrefPubMedGoogle Scholar
  • 128 Seldin DC, Choufani EB, Dember LM. , et al. Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clin Lymphoma 2003; 3 (04) 241-246
    PubMedGoogle Scholar
  • 129 Palladini G, Perfetti V, Perlini S. , et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 2005; 105 (07) 2949-2951
    CrossrefPubMedGoogle Scholar
  • 130 Sanchorawala V, Wright DG, Rosenzweig M. , et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 2007; 109 (02) 492-496
    CrossrefPubMedGoogle Scholar
  • 131 Mikhael JR, Schuster SR, Jimenez-Zepeda VH. , et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 2012; 119 (19) 4391-4394
    CrossrefPubMedGoogle Scholar
  • 132 Palladini G, Sachchithanantham S, Milani P. , et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood 2015; 126 (05) 612-615
    PubMedGoogle Scholar
  • 133 Sanchorawala V, Shelton AC, Lo S, Varga C, Sloan JM, Seldin DC. Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial. Blood 2016; 128 (08) 1059-1062
    PubMedGoogle Scholar
  • 134 Palladini G, Milani P, Foli A. , et al. A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis. Blood 2017; 129 (15) 2120-2123
    CrossrefPubMedGoogle Scholar
  • 135 Sanchorawala V, Sarosiek S, Sloan JM. , et al. Safety and tolerability of daratumumab in patients with relapsed light chain (AL) amyloidosis: preliminary results of a phase II study. Blood 2017; 130: 507
    PubMedGoogle Scholar
  • 136 Milani P, Gertz MA, Merlini G, Dispenzieri A. Attitudes about when and how to treat patients with AL amyloidosis: an international survey. Amyloid 2017; 24 (04) 213-216
    CrossrefPubMedGoogle Scholar
  • 137 Blank N, Hegenbart U, Dietrich S. , et al. Obesity is a significant susceptibility factor for idiopathic AA amyloidosis. Amyloid 2018; 25: 37-45
    CrossrefPubMedGoogle Scholar
  • 138 Lachmann HJ, Goodman HJ, Gilbertson JA. , et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007; 356 (23) 2361-2371
    CrossrefPubMedGoogle Scholar
  • 139 Tsunoda I, Awano H, Kayama H. , et al. Idiopathic AA amyloidosis manifested by autonomic neuropathy, vestibulocochleopathy, and lattice corneal dystrophy. J Neurol Neurosurg Psychiatry 1994; 57 (05) 635-637
    CrossrefPubMedGoogle Scholar
  • 140 Nakamura T, Tomoda K, Tsukano M, Yamamura Y, Baba S. Gustatory sweating due to autonomic neuropathy in a patient with amyloidosis secondary to rheumatoid arthritis. Mod Rheumatol 2004; 14 (06) 498-501
    CrossrefPubMedGoogle Scholar
  • 141 Gaspar BL, Garg C, Vasishta RK, Nada R, Goyal MK. Localised SAA amyloidosis with intra-axonal intra-myelin amyloid deposits. Pathology 2017; 49 (01) 103-105
    CrossrefPubMedGoogle Scholar
  • 142 Perfetto F, Moggi-Pignone A, Livi R, Tempestini A, Bergesio F, Matucci-Cerinic M. Systemic amyloidosis: a challenge for the rheumatologist. Nat Rev Rheumatol 2010; 6 (07) 417-429
    CrossrefPubMedGoogle Scholar
  • 143 Valleix S, Gillmore JD, Bridoux F. , et al. Hereditary systemic amyloidosis due to Asp76Asn variant β2-microglobulin. N Engl J Med 2012; 366 (24) 2276-2283
    CrossrefPubMedGoogle Scholar
  • 144 Nakagawa M, Sekijima Y, Yazaki M. , et al. Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis. Amyloid 2016; 23 (01) 58-63
    CrossrefPubMedGoogle Scholar
  • 145 Pinney JH, Whelan CJ, Petrie A. , et al. Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc 2013; 2 (02) e000098
    PubMedGoogle Scholar
  • 146 Coelho T, Maurer MS, Suhr OB. THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin 2013; 29 (01) 63-76
    CrossrefPubMedGoogle Scholar
  • 147 Lam L, Margeta M, Layzer R. Amyloid polyneuropathy caused by wild-type transthyretin. Muscle Nerve 2015; 52 (01) 146-149
    CrossrefPubMedGoogle Scholar
  • 148 Wajnsztajn F, Kim A, Boehme A, Maurer M, Brannagan T. Peripheral neuropathy in wild type transthyretin amyloidosis. (P1. 438). Neurology 2018;90(15, Suppl)
    PubMedGoogle Scholar